Sohan Shah

Sohan Shah

Auto-generated profile, based on publicly available information

Sohan Shah

The James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ATAustin Tedman
Austin Tedman
MGMuskan Goel
Muskan Goel
SSSohan Shah
Sohan Shah
JSJonathan P. Schlebach
Jonathan P. Schlebach
Several diseases of protein misfolding can now be treated with an emerging class of therapeutics known as pharmacological chaperones, pharmacochaperones, or correctors. These small molecules exploit the universal thermodynamic coupling between ligand binding and protein folding to suppress conformational defects that disrupt protein homeostasis. While the mechanistic basis of their activity is quite simple in theory, their nuanced proteostatic effects can vary depending on the intrinsic properties of their target proteins and the cellular context. Deviations in activity are especially pronounced across panels of pathogenic variants of the target protein. In this perspective, we explore the factors that shape the potency of pharmacochaperones and the intrinsic sensitivity of different target proteins in relation to various theoretical considerations and experimental observations. We discuss how emerging technologies have provided general insights into the molecular basis of the variant-specific effects of certain pharmacochaperones. We also highlight ongoing efforts to identify existing drugs that stabilize misfolded variants and to repurpose them as pharmacochaperones. Finally, we discuss how the chaperone activity of current drugs could potentially contribute to complex pharmacology and deviations in therapeutic efficacy across patient cohorts. Together, these principles provide a coherent framework that may help guide the discovery and precision targeting of next generation pharmacochaperones for both current and new targets involved in proteostasis diseases. An audio recording of this work is included in the supplement and can be freely streamed here.

14 August 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ATAustin Tedman
Austin Tedman
MGMuskan Goel
Muskan Goel
SSSohan Shah
Sohan Shah
MHMatthew K. Howard
Matthew K. Howard
LCLaura M. Chamness
Laura M. Chamness
JSJonathan P. Schlebach
Jonathan P. Schlebach
G protein-coupled receptors (GPCRs) mediate a variety of signaling pathways and represent the most common class of pharmaceutical target. While advances in structural biochemistry have provided deep functional insights into key receptors, many of the 800+ human GPCRs remain understudied. We introduce a versatile “deep receptor scanning” platform that can be used to experimentally characterize 766 human GPCRs and 174 known GPCR splice variants in parallel. We use this platform to quantitatively characterize the relative abundance of canonical and alternative receptor transcripts, their translational efficiency, and the plasma membrane expression of each receptor in the context of a recombinant pool of HEK293T cells expressing individual GPCRs. We then employ machine learning to identify specific structural features that are strongly associated with variations in GPCR expression. Our results show that many highly-expressed receptors exhibit systematic differences in hydrophobicity and secondary structure. This experimental platform and informatic approach are compatible with a variety of assays and can be used to efficiently explore the biochemical and pharmacological properties of the GPCRome.